MS Virtual Grand Rounds

Multiple Sclerosis
Virtual Grand Rounds

Risks and Benefits of Therapy I:
Focus on Natalizumab and Mitoxantrone

Print this Content

 

 

How to Obtain AMA PRA
Category 1 Credit™

  1. Listen to the audio discussion.
  2. Complete the CME posttest (each question must be answered correctly).
  3. Login to your account.
  4. Complete the credit and evaluation form.
  5. Print your personalized CME certificate.

Technical Requirements

  

Release Date:  September 30, 2011
Expiration Date: September 30, 2012

Estimated Time of Completion: 1 hour

Description

The purpose of this activity is to review efficacy and safety data pertaining to mitoxantrone and natalizumab for use in patients with multiple sclerosis (MS).

Learning Objectives

  1. Describe the benefits and risks of mitoxantrone treatment in patients with multiple sclerosis (MS).
  2. Assess the benefits and risks of natalizumab treatment in patients with MS.
  3. Identify the risks and benefits of using either mitoxantrone or natalizumab in several clinical scenarios.

Target Audience

The target audience consists of neurologists and other healthcare professionals who manage patients with multiple sclerosis.

Accreditation

The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Cleveland Clinic Foundation Center for Continuing Education designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association Council on Continuing Medical Education for Category 2 credit.

Activity Director

Alexander Rae-Grant, MD
Cleveland Clinic Neurological Institute
Mellen School for Multiple Sclerosis Treatment and Research
Cleveland Clinic
Cleveland, Ohio

Faculty

J. Theodore Phillips, MD, PhD, FAAN
Baylor Institute for Immunology Research
Baylor University Medical Center
Dallas, Texas

Disclosures

In accordance with the Standards for Commercial Support issued by the Accreditation Council for Continuing Medical Education (ACCME), The Cleveland Clinic Foundation Center for Continuing Education requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias.

The following faculty have indicated that they may have a relationship which, in the context of their presentation, could be perceived as a potential conflict of interest:

Alexander Rae-Grant, MD

Biogen Idec: Teaching and Speaking

Novartis Pharmaceuticals Corporation: Teaching and Speaking

Teva Neuroscience, Inc.: Teaching and Speaking

 

J. Theodore Phillips, MD, PhD, FAAN

Biogen Idec: Teaching and Speaking

Novartis Pharmaceuticals Corporation: Teaching and Speaking

Teva Neuroscience, Inc.: Teaching and Speaking
 

The Cleveland Clinic Foundation Center for Continuing Education acknowledges
educational grants for partial support of this activity from:
Bayer HealthCare Pharmaceuticals; Biogen Idec; Teva Neuroscience, Inc.

This CME activity was produced by the Cleveland Clinic Center for Continuing Education,
Cleveland Clinic Neurological Institute and  

CME Disclaimer